MGNX MacroGenics, Inc.
Price Chart
Executive Summary
MacroGenics announced that the FDA has lifted the partial clinical hold on its Phase 2 LINNET study of lorigerlimab for gynecologic cancers, allowing resumption of new patient enrollment under a revised protocol. The company remains on track to provide a mid-2026 clinical update.
Actionable Insight
Resumption of enrollment removes a key regulatory overhang; traders should position ahead of the mid-2026 clinical update as next major catalyst. Watch for protocol refinement details and safety data in upcoming disclosures.
Key Facts
- FDA lifted the partial clinical hold on the Phase 2 LINNET study of lorigerlimab.
- Enrollment of new patients will resume with additional risk-mitigation measures for hematologic and cardiac toxicities.
- Study evaluates lorigerlimab in platinum-resistant ovarian cancer and clear cell gynecologic cancer with an ORR primary endpoint.
- 41 patients have already been dosed in the LINNET study; over 300 patients dosed across all lorigerlimab trials to date.
- Mid-year 2026 update expected for the program.
Financial Impact
Non-dilutive near-term value catalyst; de-risks lorigerlimab development path
Risk Factors
- Potential for renewed safety concerns given prior hematologic and cardiac toxicities.
- Mid-2026 timeline for data readout implies limited near-term catalysts.
- Market cap remains small ($213M), increasing volatility risk on future updates.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3270538 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 13, 2026
10d ago
|
8-K
| $4.16 $4.16 | · 0.00% | ▼ −0.01% | $4.53 (+8.89%) |
|
May 12, 2026
11d ago
|
8-K
| $3.52 $3.45 | ▼ −1.99% | ▼ −2.56% | $4.53 (+28.69%) |
|
May 11, 2026
12d ago
|
Press Release
| $3.52 $3.52 | · 0.00% | ▼ −0.54% | $4.53 (+28.69%) |
|
Apr 8, 2026
6w ago
|
8-K
| $3.44 $3.60 | ▲ +4.65% | ▲ +4.71% | $4.53 (+31.69%) |
|
Apr 8, 2026
6w ago
|
Press Release
| $3.44 $3.60 | ▲ +4.65% | ▲ +4.71% | $4.53 (+31.69%) |
|
Apr 8, 2026
6w ago
|
DEFA14A
| $3.44 $3.60 | ▲ +4.65% | ▲ +4.71% | $4.53 (+31.69%) |
|
Feb 28, 2026
12w ago
|
Institutional Cluster
| $1.94 $1.90 | ▼ −2.06% | ▼ −1.15% | $4.53 (+133.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access